V2 receptor antagonist; tolvaptan

Electrolyte and Blood Pressure

Volumn 9, Issue 2, 2011, Pages 50-54

  Yi, Joo Hark ^a   Shin, Hyun Jong ^a   Kim, Ho Jung ^a  

^a Hanyang University Guri Hospital   (South Korea)

Author keywords

Arginine vasopressin receptors; Hyponatremia; Tolvaptan

Indexed keywords

ARGININE; CONIVAPTAN; LIXIVAPTAN; RELCOVAPTAN; SATAVAPTAN; SODIUM; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN V1A RECEPTOR; VASOPRESSIN V1B RECEPTOR; VASOPRESSIN V2 RECEPTOR;

ANOREXIA; DRUG CONTRAINDICATION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERVOLEMIA; HYPONATREMIA; IRRITABILITY; LIVER CIRRHOSIS; POLLAKISURIA; POLYURIA; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SODIUM BLOOD LEVEL; THIRST; TREATMENT DURATION; UREMIA; XEROSTOMIA;

EID: 84870162324     PISSN: 17385997     EISSN: 20929935     Source Type: Journal    
DOI: 10.5049/EBP.2011.9.2.50     Document Type: Review

References (20)

1. Verbalis JG: The syndrome of inappropriate antidiuretic hormone secretion and other hypoosmolar disorders. In: Diseases of the kidney and urinary tract. 1st ed., Philadelphia, Lippincott Williams & Wilkins, 2007, p2214-2248
2. Schrier RW: Body water homeostasis: clinical disorders of urinary dilution and concentration. J Am Soc Nephrol 17:1820-1832, 2006
3. Goldberg A, Hammerman H, Petcherski S, et al.: Hyponatremia and long-term mortality in survivors of acute ST-elevation myocardial infarction. Arch Intern Med 166:781-786, 2006
4. De Luca L, Klein L, Udelson JE, et al.: Hyponatremia in patients with heart failure. Am J Cardiol 96:19L-23L, 2005
5. Wu CC, Yeung LK, Tsai WS, et al.: Incidence and factors predictive of acute renal failure in patients with advanced liver cirrhosis. Clin Nephrol 65:28-33, 2006
6. Bhardwaj A: Neurological impact of vasopressin dysregulation and hyponatremia. Ann Neurol 59:229-236, 2006
7. Guyton AC: The body fluids and kidneys. In: Textbook of medical physiology. Philadelphia (PA), WB Saunders Company, 2006, p291-414
8. Brooks VL, Keil LC, Reid IA: Role of the renin-angiotensin system in the control of vasopressin secretion in conscious dogs. Circ Res 58: 829-838, 1986 (Pubitemid 16094212)
9. Verbalis JG: Vasopressin V2 receptor antagonists. J Mol Endocrinol 29:1-9, 2002
10. Lolait SJ, O'Carroll AM, Mahan LC, et al.: Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A 92:6783-6787, 1995
11. Nielsen S, Kwon TH, Christensen BM, Promeneur D, Frokiaer J, Marples D: Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 10:647-663, 1999 (Pubitemid 29117647)
12. Yamamura Y, Ogawa H, Yamashita H, et al.: Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 105:787-791, 1992
13. Samsca (tolvaptan tablets for oral use) [package insert]. Tokyo, Japan, Otsaka Pharmaceutical, 2009.
14. Costello-Boerrigter LC, Boerrigter G, Burnett JC, Jr.: Pharmacology of vasopressin antagonists. Heart Fail Rev 14:75-82, 2009
15. Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 371:1624-1632, 2008 (Pubitemid 351626846)
16. Schrier RW, Gross P, Gheorghiade M, et al.: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355:2099-2112, 2006 (Pubitemid 44749318)
17. Berl T, Quittnat-Pelletier F, Verbalis JG, et al.: Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 21: 705-712, 2010
18. Gheorghiade M, Orlandi C, Burnett JC, et al.: Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). J Card Fail 11:260-269, 2005 (Pubitemid 40626781)
19. Konstam MA, Gheorghiade M, Burnett JC, Jr., et al.: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297:1319-1331, 2007 (Pubitemid 46513233)
20. Gheorghiade M, Konstam MA, Burnett JC, Jr., et al.: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297:1332-1343, 2007 (Pubitemid 46513234)